Patent · US Active

Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF

US8008009B2 · kind B2 · utility

35Cited by
0References
19Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJan 30, 2007
Grant dateAug 30, 2011
Priority date
Expiry dateFeb 14, 2027

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/48
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention concerns a method for in vitro diagnosis of cancer, in particular breast, thyroid or lung cancer, which consists in determining the presence of ProNGF in a biological sample derived from a patient suspected of suffering from cancer, in particular breast, thyroid or lung cancer. Said method may be used for early diagnosis, screening, therapeutic follow-up, prognosis and for diagnosing relapses in cancer and in particular breast, thyroid or lung cancer.The present invention also concerns the use of a ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer.The invention is applicable in the field of diagnosis and therapeutics.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.